Randomized Clinical Trial of First-Line Genome Sequencing in Pediatric White Matter Disorders

Adeline Vanderver*, Genevieve Bernard, Guy Helman, Omar Sherbini, Ryan Boeck, Jeffrey Cohn, Abigail Collins, Scott Demarest, Katherine Dobbins, Lisa Emrick, Jamie Fraser, Diane Masser-Frye, Jean Hayward, Swati Karmarkar, Stephanie Keller, Samuel Mirrop, Wendy Mitchell, Sheel Pathak, Elliott Sherr, Keith van HarenErica Waters, Jenny L. Wilson, Leah Zhorne, Raphael Schiffmann, Marjo S. van der Knaap, Amy Pizzino, Holly Dubbs, Justine Shults, Cas Simons, Ryan J. Taft, LeukoSEQ Workgroup

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objective: Genome sequencing (GS) is promising for unsolved leukodystrophies, but its efficacy has not been prospectively studied. Methods: A prospective time-delayed crossover design trial of GS to assess the efficacy of GS as a first-line diagnostic tool for genetic white matter disorders took place between December 1, 2015 and September 27, 2017. Patients were randomized to receive GS immediately with concurrent standard of care (SoC) testing, or to receive SoC testing for 4 months followed by GS. Results: Thirty-four individuals were assessed at interim review. The genetic origin of 2 patient's leukoencephalopathy was resolved before randomization. Nine patients were stratified to the immediate intervention group and 23 patients to the delayed-GS arm. The efficacy of GS was significant relative to SoC in the immediate (5/9 [56%] vs 0/9 [0%]; Wild–Seber, p < 0.005) and delayed (control) arms (14/23 [61%] vs 5/23 [22%]; Wild–Seber, p < 0.005). The time to diagnosis was significantly shorter in the immediate-GS group (log-rank test, p = 0.04). The overall diagnostic efficacy of combined GS and SoC approaches was 26 of 34 (76.5%, 95% confidence interval = 58.8–89.3%) in <4 months, greater than historical norms of <50% over 5 years. Owing to loss of clinical equipoise, the trial design was altered to a single-arm observational study. Interpretation: In this study, first-line GS provided earlier and greater diagnostic efficacy in white matter disorders. We provide an evidence-based diagnostic testing algorithm to enable appropriate clinical GS utilization in this population. ANN NEUROL 2020.

Original languageEnglish
JournalAnnals of Neurology
DOIs
Publication statusAccepted/In press - 1 Jan 2020

Cite this

Vanderver, A., Bernard, G., Helman, G., Sherbini, O., Boeck, R., Cohn, J., ... LeukoSEQ Workgroup (Accepted/In press). Randomized Clinical Trial of First-Line Genome Sequencing in Pediatric White Matter Disorders. Annals of Neurology. https://doi.org/10.1002/ana.25757